SOPHiA GENETICS SA (NASDAQ:SOPH) Short Interest Update

SOPHiA GENETICS SA (NASDAQ:SOPH) was the target of a significant increase in short interest during the month of June. As of June 30th, there was short interest totaling 636,132 shares, an increase of 141.3% from the June 15th total of 263,601 shares. Based on an average daily volume of 459,329 shares, the short-interest ratio is currently 1.4 days. Approximately 0.8% of the shares of the company are sold short.

Analyst Upgrades and Downgrades

Several equities analysts recently weighed in on SOPH shares. Weiss Ratings restated a “sell (d-)” rating on shares of SOPHiA GENETICS in a research report on Tuesday, April 21st. BTIG Research reiterated a “buy” rating and issued a $8.00 target price on shares of SOPHiA GENETICS in a research note on Monday, June 15th. Two equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus price target of $7.50.

SOPHiA GENETICS Stock Performance

NASDAQ SOPH traded down $0.06 on Tuesday, hitting $5.66. 13,763 shares of the stock traded hands, compared to its average volume of 189,605. The company has a debt-to-equity ratio of 1.05, a quick ratio of 1.90 and a current ratio of 2.06. The business’s fifty day moving average is $5.18 and its two-hundred day moving average is $4.99. SOPHiA GENETICS has a 12 month low of $2.92 and a 12 month high of $6.30. The firm has a market capitalization of $474.48 million, a price-to-earnings ratio of -10.85 and a beta of 0.96.

SOPHiA GENETICS (NASDAQ:SOPH) last issued its earnings results on Tuesday, May 5th. The company reported ($0.27) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.23) by ($0.04). SOPHiA GENETICS had a negative net margin of 44.48% and a negative return on equity of 62.74%. The firm had revenue of $21.69 million during the quarter, compared to the consensus estimate of $20.40 million.

Insiders Place Their Bets

In other SOPHiA GENETICS news, insider Zhenyu Xu sold 7,393 shares of the company’s stock in a transaction on Monday, July 6th. The stock was sold at an average price of $5.17, for a total value of $38,221.81. Following the completion of the transaction, the insider owned 614,887 shares in the company, valued at $3,178,965.79. This represents a 1.19% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, insider Philippe Menu sold 7,393 shares of the company’s stock in a transaction on Monday, July 6th. The shares were sold at an average price of $5.16, for a total value of $38,147.88. Following the completion of the transaction, the insider owned 233,387 shares of the company’s stock, valued at $1,204,276.92. This trade represents a 3.07% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. In the last 90 days, insiders have sold 184,243 shares of company stock valued at $987,562. 4.88% of the stock is currently owned by insiders.

Institutional Investors Weigh In On SOPHiA GENETICS

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Perkins Capital Management Inc. purchased a new stake in SOPHiA GENETICS during the fourth quarter valued at about $49,000. Squarepoint Ops LLC bought a new position in SOPHiA GENETICS during the third quarter worth about $49,000. First Dallas Securities Inc. purchased a new position in shares of SOPHiA GENETICS in the first quarter worth about $50,000. Quadrature Capital Ltd purchased a new position in shares of SOPHiA GENETICS in the fourth quarter worth about $54,000. Finally, XTX Topco Ltd purchased a new position in shares of SOPHiA GENETICS in the fourth quarter worth about $55,000. 31.59% of the stock is currently owned by institutional investors.

SOPHiA GENETICS Company Profile

SOPHiA GENETICS SA is a data-driven medicine company founded in 2011 and headquartered in La Tène, Switzerland. The firm develops and operates a cloud-native software platform designed to standardize and analyze complex genomic and radiomic data. Its core offering, the SOPHiA DDM™ platform, leverages artificial intelligence and machine learning algorithms to help healthcare institutions, laboratories and biopharmaceutical partners derive actionable insights from next-generation sequencing and medical imaging datasets.

The SOPHiA DDM™ platform supports a range of clinical applications, including oncology, hereditary diseases and rare genetic disorders.